Syncom Formu (I) Ltd

NSE: SYNCOMF · Pharmaceuticals · sector

₹20.05NSE close 2026-10-26

Key numbers

Market cap₹1,885 cr

Price₹20.05

52w high / low₹27 / ₹10

P/E21.3xSector median 27.9x

P/B4.5xSector median 2.9x

Book value₹4.4

Dividend yield–Sector median 0.48%

ROE22.6%Sector median 11.7%

ROCE27.4%Sector median 12.3%

OPM17.6%Sector median 14.0%

Debt / equity0.00xSector median 0.16x

EV/EBITDA20.2xSector median 18.6x

Interest cover99.4x

Current ratio3.18x

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG0.44x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹113 cr vs borrowings ₹1 cr (FY26): cash is higher (net cash).
Operating profit covered interest 99.4x in the last 12 months.
Operating cash flow was below net profit in 3 of the last 3 years (FY26, FY25, FY24).
Revenue was higher than a year earlier in 2 of the last 4 quarters.
Other income was 39% of net profit in the last 12 months.
Debtor days went from 143 (FY24) to 82 (FY26).
No dividend in the last 3 financial years.
Price ₹20.05 on 2026-10-26: -27.1% from the 52-week high, +96.4% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹23.96 · low ₹11.17

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	102	128	149	117	122	115	135	126
EBITDA	12	15	18	16	18	21	22	26
OPM %	11.9%	11.6%	11.9%	13.6%	15.1%	18.4%	16.3%	20.9%
Other income	4	4	7	6	5	6	15	8
Net profit	11	13	18	16	17	19	25	25
EPS (₹)	0.16	0.14	0.16	0.21	0.18	0.23	0.27	0.26
Revenue YoY					+19.0%	-9.7%	-9.0%	+7.4%
Profit YoY					+49.4%	+45.5%	+42.3%	+57.8%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY24	FY25	FY26	TTM
Revenue	263	465	489	498
EBITDA	30	54	77	88
Net profit	25	49	76	86
EPS (₹)	0.34	0.57	0.81	0.94
Revenue growth		+76.5%	+5.2%	+0.4%
Profit growth		+95.3%	+54.6%	+48.6%
Dividend / share (₹)	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	+0.4%
Net profit	–	–	+48.6%
EPS	–	–	–
Share price	–	+5.2% (2y)	+31.6%

Balance sheet

₹ cr	FY24	FY25	FY26
Shareholders' equity	288	342	415
Borrowings	72	5	1
Cash & equivalents	132	90	113
Total assets	405	413	534
Fixed assets	72	78	90
Capital work in progress	0	0	0
Investments	2	4	3
Receivables	103	108	110
Inventory	21	41	63
Payables	24	43	74

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY24	FY25	FY26
Cash from operations	-6	23	58
Cash from investing	83	-18	-51
Cash from financing	-15	-68	-3
Capex	8	10	12
Free cash flow	-14	13	46

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY24	FY25	FY26
ROE %	8.8%	14.4%	18.4%
ROCE %	10.7%	19.1%	24.6%
Debtor days	143	84	82
Inventory days	49	49	81
Payable days	56	51	96
Cash conversion cycle (days)	136	82	67
Working capital days	233	165	169

Shareholding

Holder	% (2026-09-30)
Promoters	50.57%
FIIs	2.22%
DIIs	0.00%
of which Mutual funds	0.00%
Government	0.00%
Public (non-institutions)	47.20%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%

Promoter group	%
Kedarmal Shankarlal Bankda	12.44%
Vijay Shankarlal Bankda	10.48%
Paradise Vyapar Private Limited	5.02%
Ankit Bankda	4.99%
Asha Vijay Bankda	4.90%
Vimla Bankda	4.26%
Strand Developers PVT Ltd	3.82%
Vijay Bankda HUF	1.28%
Payal Ankur Bankda	1.25%
Kedarmal Shankarlal Bankda HUF	1.12%
Sulabh Rahul Bankda	0.99%
Rahul Bankda	0.02%
Ankur Vijay Bankda	0.01%

4,18,465 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
SYNCOMF	₹1,885 cr	21.3x	4.5x	22.6%	27.4%	17.6%	–	–

All 185 companies in Pharmaceuticals →

Business segments (FY26)

Segment	Revenue	Share	EBIT	Margin
Pharmaceuticals Drugs & Formulations	₹516 cr	99.1%	₹99 cr	19.3%
Renting of Property	₹4 cr	0.7%	₹3 cr	81.1%
Trading of Commodities	₹1 cr	0.2%	₹0 cr	-2.4%

Dividends & corporate actions

Ex-date	Action	Detail
2026-09-23	Dividend	Dividend - Re 0.10 Per Share
2024-09-23	Other	Annual General Meeting
2023-09-18	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company

Manufacture of Pharmaceuticals: Development, manufacturing & sale of pharmaceutical products


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	SYNCOMF
BSE code	524470
ISIN	INE312C01025
Face value	₹1.0
Incorporated	1988-06-21
Website	www.syncomformulations.com
Plants (India / abroad)	1 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.